Topic Highlight
Copyright ©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jun 28, 2012; 18(24): 3050-3057
Published online Jun 28, 2012. doi: 10.3748/wjg.v18.i24.3050
Pathogenesis of achalasia cardia
Uday C Ghoshal, Sunil B Daschakraborty, Renu Singh
Uday C Ghoshal, Sunil B Daschakraborty, Renu Singh, Department of Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow 226104, India
Author contributions: Ghoshal UC made substantial contributions to conception, drafting and revising the manuscript critically for important intellectual content; Daschakraborty SB and Singh R made substantial contributions during writing of the first draft of the paper; all authors approved the version to be published.
Correspondence to: Uday C Ghoshal, MD, DNB, DM, FACG, Additional Professor, Department of Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, India. udayghoshal@gmail.com
Telephone: +91-522-2494405 Fax: +91-522-2668017
Received: June 25, 2011
Revised: October 11, 2011
Accepted: April 28, 2012
Published online: June 28, 2012

Abstract

Achalasia cardia is one of the common causes of motor dysphagia. Though the disease was first described more than 300 years ago, exact pathogenesis of this condition still remains enigmatic. Pathophysiologically, achalasia cardia is caused by loss of inhibitory ganglion in the myenteric plexus of the esophagus. In the initial stage, degeneration of inhibitory nerves in the esophagus results in unopposed action of excitatory neurotransmitters such as acetylcholine, resulting in high amplitude non-peristaltic contractions (vigorous achalasia); progressive loss of cholinergic neurons over time results in dilation and low amplitude simultaneous contractions in the esophageal body (classic achalasia). Since the initial description, several studies have attempted to explore initiating agents that may cause the disease, such as viral infection, other environmental factors, autoimmunity, and genetic factors. Though Chagas disease, which mimics achalasia, is caused by an infective agent, available evidence suggests that infection may not be an independent cause of primary achalasia. A genetic basis for achalasia is supported by reports showing occurrence of disease in monozygotic twins, siblings and other first-degree relatives and occurrence in association with other genetic diseases such as Down’s syndrome and Parkinson’s disease. Polymorphisms in genes encoding for nitric oxide synthase, receptors for vasoactive intestinal peptide, interleukin 23 and the ALADIN gene have been reported. However, studies on larger numbers of patients and controls from different ethnic groups are needed before definite conclusions can be obtained. Currently, the disease is believed to be multi-factorial, with autoimmune mechanisms triggered by infection in a genetically predisposed individual leading to degeneration of inhibitory ganglia in the wall of the esophagus.

Key Words: Esophagus, Motor dysphagia, Motility disorder, Peristalsis, Esophageal sphincter


Citation: Ghoshal UC, Daschakraborty SB, Singh R. Pathogenesis of achalasia cardia. World J Gastroenterol 2012; 18(24): 3050-3057
INTRODUCTION

Achalasia is an esophageal motor disorder characterized by aperistalsis of the esophageal body and lack of relaxation of the lower sphincter in response to swallows. It affects both sexes and all age groups[1,2]. Achalasia was first described by Willis[3] in 1674 as “food blockage in esophagus”. He treated these patients successfully with a dilator made of whale bone and sponge[3]. The term “achalasia” was first coined by Hurst[4] in 1927. He had observed such patients since 1914 and suggested that their disorder might be due to absence of normal relaxation of the sphincter, possibly resulting from organic changes in Auerbach’s plexus[5]. Achalasia is a Greek word that means “failure of relaxation”. Achalasia can be primary (idiopathic) or secondary. In secondary achalasia, the cause for the degeneration of esophageal nerve fibers is known. Pathophysiologically, achalasia is caused by loss of inhibitory ganglion cells in the myenteric plexus. Since the initial description, several studies have attempted to explore initiating agents that may cause the disease such as viral infection, other environmental factors, autoimmunity, and genetic factors. However, the exact pathogenesis of primary achalasia is still not known. In this paper, the literature regarding pathogenesis of primary achalasia is reviewed.

PATHOPHYSIOLOGICAL ISSUES

The pathophysiology of achalasia is outlined in a simplified manner in Figure 1. In healthy esophagus, progressive delay in contractility of the lower esophageal muscles results from the presence of inhibitory neurotransmitters such as nitric oxide and its receptors in the lower esophagus (Figure 1)[6,7]. In the initial stage of the disease, degeneration of inhibitory nerve fibers in the esophagus results in unopposed action of excitatory neurotransmitter such as acetylcholine, which leads to high amplitude non-peristaltic contractions (not progressively delayed or simultaneous)[8]. This stage of achalasia is known as vigorous achalasia (average amplitude of contractions in lower esophagus > 40 mmHg)[9]. Progressive loss of cholinergic neurons results in dilation and low amplitude simultaneous contractions in the esophageal body; this stage of achalasia is called classic achalasia. Studies demonstrating reduction in number of ganglion cells in the esophageal body at autopsy of patients with achalasia and an inverse correlation between number of ganglion cells and duration of disease support their involvement in the disease process[8]. In experimental studies published long ago, a muscles strip obtained from the esophageal body of patients with esophageal achalasia failed to contract on addition of the ganglion stimulant nicotine though it contracted in response to acetylcholine, which is a direct muscle stimulant. A muscle strip from the lower esophageal sphincter (LES) of patients with achalasia contracted in response to acetylcholine though it failed to relax in response to nicotine[10]. These findings demonstrate that in patients with achalasia, there is degeneration of ganglia though the muscles remain contractile in response to acetylcholine. Degeneration of inhibitory control of the LES has also been demonstrated by studies that showed cholecystokinin, which reduces LES pressure in healthy subjects, increases pressure in patients with achalasia[8]; esophageal distension failed to cause relaxation of LES in these patients[11] and gastric distension failed to induce transient LES relaxation[12]. All the above data suggest that achalasia results from degeneration of the esophageal nerve plexus, particularly the inhibitory fibers. However, neural degeneration might not be confined to the esophagus alone as evidenced by demonstration of Wallerian degeneration in the vagus nerve on electron microscopy[13], improvement in some abnormalities with stimulation of vagus nerve in animal models[14,15], presence of Lewy bodies in the brainstem of patients with achalasia[16], and delayed gastric emptying[17] and abnormal gastric secretory response to insulin-induced hypoglycemia in a subset of patients[18]. It is, however, not clear why some people develop neural degeneration causing achalasia. The various environmental, autoimmune and genetic factors incriminated in pathogenesis are reviewed below.

Figure 1
Figure 1 Schematic diagram outlining possible pathogenesis of achalasia cardia. A: Diagram showing distribution of nitric oxide (NO) and acetycholine (Ach) neurons in the esophagus with normal motility pattern and barium esophagogram; B: Loss of NO in esophagus in early stage of the disease resulting in high amplitude simultaneous contractions in body (called vigorous achalasia). In this stage esophagus is not dilated in barium esophagogram; C: Further degeneration of inhibitory and additional degeneration of excitatory neurons causes low amplitude simultaneous contractions in esophageal body (called classic achalasia). In this stage esophagus is dilated in barium esophagogram. NANC: Non-adrenergic, non-cholinergic.

A study in an animal model showed that the nitric oxide inhibitor, recombinant human hemoglobin, caused incomplete LES relaxation and high amplitude simultaneous contractions in the body of the esophagus[19]. Similar results have been reported in humans[20]. Another study in an animal model failed to show an association of intramuscular interstitial cells of Cajal in the nitrenergic pathway and dysfunction of LES found in achalasia[21].

Infection

A number of studies implicating viral agents in the pathogenesis of achalasia showed conflicting results. An initial report by Jones et al[22] showed a statistically significant increase in antibody titer against measles virus (MV) in patients with achalasia compared with controls (14 of 21 achalasia patients vs 7 of 21 controls, P < 0.05). This difference persisted only at a titer of 1/32 or more. However, there was similar frequency of infection in both groups as was evident by similar antibody detection rates at low titer[22].

Robertson et al[23] reported an association between Varicella zoster virus (VZV) infection in patients with achalasia by demonstrating viral DNA in esophageal tissue. They demonstrated VZV particles by DNA hybridization techniques in three of nine esophageal myotomy specimens from achalasia patients, but in none from 20 control subjects. DNA probes for cytomegalovirus (CMV) and herpes simplex virus type 1 (HSV-1) were negative in both achalasia patients and controls[23]. This study provided an attractive hypothesis, but failed to establish a causal association. We have reported one patient who presented with motor dysphagia due to esophageal hypomotility and also developed gastroparesis following infection with VZV[24].

A few studies, however, failed to show evidence of infection as a cause for achalasia[25,26]. Niwamoto et al[25] used polymerase chain reaction to detect human herpes virus DNA (HSV-1 and 2, CMV, VZV, Epstein-Barr virus and human herpes virus-6) or MV RNA in the esophageal muscle of 12 patients with achalasia and six with upper esophageal carcinoma. Only HSV-1 and 2 were detected in all samples including patients and controls. Other viruses were not detected. Similarly, another study failed to detect human herpes virus, MV and human papilloma virus sequences both in achalasia or control specimens[26]. Two studies proposed an association between MV and VZV infection in patients with achalasia[22,23]. However, VZV particles were found only in a third of achalasia patients[23]. Moreover, not all patients with VZV and MV infection develop achalasia. It has been hypothesized that most patients might have cleared virus or there could be sampling error. However, most of these data suggest that VZV may not be an important cause of achalasia.

Considering the above possibilities, a recent study tried to demonstrate infection in the absence of direct evidence of virus in esophageal tissue. Facco et al[27] reported oligoclonal selection of T cells in achalasia patients by flow cytometry and CDR3 length spectra typing analysis of lymphocytes. They also demonstrated increased proliferation of T cells and Th-1 type cytokine release in response to HSV-1 antigen. In conclusion, available evidence suggests that infection may not be a definite cause for esophageal achalasia. One strong piece of evidence in favor of infection in the pathogenesis of achalasia, however, is the fact that Chagas disease, caused by Trypanosoma cruzi, very closely mimics the pathophysiology of primary achalasia[28].

Immunological factors

An autoimmune etiology for achalasia has been considered because of the presence of neural inflammation in absence of conclusive evidence of infection. Studies have demonstrated inflammatory cell infiltrate of the myenteric plexus in 90%-100% of esophageal specimens from achalasia patients[29,30]. This hypothesis has been further supported by the presence of autoantibody in sera of patients with achalasia (Table 1) and an association with major histocompatibility complex class II antigen (Table 2). Immune activation and inflammation is known to be associated with altered gastrointestinal motility due to neural dysfunction in the gut[31]. Taking the analogy of other gastrointestinal motility disorders such as post-infectious irritable bowel syndrome, intestinal pseudo-obstruction and ileus, it has been postulated that achalasia may have a similar pathophysiological basis[31]. However, more studies are needed on this issue.

Table 1 Studies comparing autoantibody levels between achalasia patients and control subjects.
AuthorsTestsAutoantibody, n/N (%)
P value
AchalasiaControl
Storch et al[32]Indirect immunofluorescence37/58 (64)4/54 (7) in healthy< 0.0001
Absent in 12 of Hirschsprung’s disease
Absent in 12 esophageal cancer
Verne et al[33]Double-label Indirect immunofluorescence7/18 (40)Absent in 22 healthy< 0.05
Absent in 9 GERD
Ruiz-de-León et al[34]Indirect immunofluorescence50/92 (54.3)3/40 (7.5)< 0.001
Moses et al[36]Immunohistochemistry23/45 (51)2/22 (9) in healthy control< 0.001
8/16 (50) of GERDNS
Table 2 Studies showing association between achalasia and human leukocyte antigen.
AuthorsAlleleAllele frequency, n/N (%)
Pc valueAutoantibody in achalasia, n/N (%)
P value
AchalasiaControlAM positiveAM negative
Ruiz-de-León et al[34]DQA1*010327/92 (29.3)40/275 (14.5)< 0.0222/50 (44)5/42 (20)< 0.02
DQB1*060323/92 (25)33/275 (12)0.0519/50 (38)4/42 (10)0.05
Latiano et al[40]DQB1*0502(10.2)(4.1)0.016Antineuronal antibodies:10/41 (24.4) in achalasiaNone in controlsBoth HLA risk allele and antibody: in one patientNone in controls
DQB1*0601(5.93)(0.51)0.001
DQA1--NS

Autoantibodies in achalasia: Several studies showed a higher prevalence of autoantibodies in achalasia patients compared to controls. Storch et al[32] suggested a role of autoimmunity by demonstrating a higher prevalence of anti-myenteric autoantibody in achalasia patients (64%) compared to healthy controls (7%). They also showed absence of anti-myenteric autoantibody in Hirschsprung’s disease as well as in esophageal cancer patients, and in 8%-9% of patients with peptic esophagitis and myasthenia gravis[32]. This hypothesis was further supported by subsequent studies[33,34].

Another interesting study demonstrated that patients with Chagasic achalasia more often had autoantibodies against muscarinic acetylcholine receptors [M(2) mAchR] as compared to patients with achalasia not resulting from Chagas disease[35].

Verne et al[33] tried to demonstrate the presence of regional and cellular specific antibody in achalasia patients. Staining of the esophageal and intestinal sections of rat with sera from achalasia patients showed binding of antibody to neurons in the esophageal as well as intestinal sections, though none of the sera of patients with gastroesophageal reflux disease (GERD) or controls showed staining[33]. Since idiopathic achalasia is primarily a disorder of esophageal smooth muscles, binding on intestinal sections may suggest non-specific binding of this antibody and hence, may not suggest a causal association.

A study by Moses et al[36] demonstrated a similar degree of immune-reactivity in the myenteric plexus of the esophagus and ileum of guinea-pig and mouse when immune-stained with sera of achalasia and GERD patients; however, both the groups had higher immune-reactivity when compared with normal individuals. Western blotting analysis failed to reveal specific myenteric neuronal proteins that could be targeted by antibodies in achalasia or GERD serum[35]. These observations do not support anti-neuronal antibodies to be causative in achalasia. These antibodies may perhaps be an epiphenomenon.

Human leukocyte antigen association: An association between achalasia and human leukocyte antigen (HLA) class II histocompatibility antigens was proposed for the first time by Wong et al[37]. They performed HLA typing on 40 achalasia patients and found that Caucasians and black populations with DQw1 had 4.2 and 3.6 times higher risk of developing achalasia, respectively[37]. Subsequent studies[38,39] demonstrated associations between achalasia and HLA-DQA1*0101 allele, DQB1*0602 allele and DRB1*15 allele, and confirmed the findings reported by Wong et al[37]. Another study showed higher frequency of DQA1*0103, DQB1*0603 and DQA1*0103-DQB1*0603 heterodimer in patients with achalasia compared to controls. They also demonstrated that achalasia patients with DQA1*0103 and DQB1*0603 alleles had significantly higher prevalence of anti-myenteric antibody[34]. In contrast, Latiano et al[40] failed to show any correlation among HLA alleles and anti-neuronal antibodies. However, achalasia patients had higher frequency of DQB1*0502 and DQB1*0601 alleles. All these reports might suggest an autoimmune etiology of achalasia; however, not all patients with achalasia had predisposing HLA while not all people with the specific HLA had the disease.

In conclusion, all these data are not sufficient to conclude that achalasia is an autoimmune disease. To define a disease as autoimmune in nature, the disease should provide the following three features: (1) direct evidence based on transfer of disease by antibodies; (2) indirect evidence based on reproduction of autoimmune disease in an animal or genetic model; and (3) detection of autoreactive T cells in the target organ of disease[41]. To date, all the evidence to support an autoimmune etiology of achalasia has not been substantiated. More studies are needed on this issue.

Genetic factors: Some evidence supports a genetic basis for achalasia. The disease has been reported in monozygotic twins[42] and siblings[43-45]. A few reports described familial occurrence of achalasia cardia[46]. Studies showed genetic correlations of the ALADIN gene in achalasia associated with Allgrove syndrome[47,48]. Additionally, the disease has also been reported in association with other genetic diseases such as Down’s syndrome and Parkinson disease[49,50]. The genetic basis for achalasia might have been underestimated, in contrast to that for Hirschsprung’s disease, though both these enteric neuropathies have several features in common[51]. Hirschsprung’s disease, like achalasia, is also known to have familial occurrence and the former has been reported quite commonly in different syndromes with a genetic basis. Both the conditions have altered motor function with loss of inhibitory innervation[51]. We wish to review some studies on genetic polymorphisms in certain genes in patients with achalasia cardia.

Nitric oxide synthase polymorphism: Nitric oxide is a necessary inhibitory neurotransmitter of the esophageal myenteric plexus involved in esophageal sphincter relaxation. Nitric oxide synthase (NOS) synthesizes nitric oxide from L-arginin. Reported studies showed that in patients with achalasic cardia, the LES has less NOS compared with controls[52,53]. At present, three different NOS isozymes, neuronal NOS (NOS1), inducible NOS (NOS2) and endothelial NOS (NOS3) have been reported. NOS1, NOS2 and NOS3 genes are located on human chromosomes 12q24.2, 17q11.2-q12 and 7q36, respectively. A microsatellite (CA repeat) polymorphism is found within the 3’-untranslated region of exon 29 of the NOS1 gene. The NOS2 gene has two biallelic polymorphisms in exons 16 and 22 representing C/T and G/A transitions, respectively, and NOS3 shows a 27-bp variable number of tandem repeat polymorphisms in intron 4. Published studies have failed to explain a strong role for these functional polymorphisms in the susceptibility for achalasia[54,55].

VIPR1 gene polymorphism: The VIPR1 gene is located on human chromosome 3p22[56]. Vasoactive intestinal peptide is a small neuropeptide, which acts as a neurotransmitter with anti-inflammatory properties; it is present in the myenteric plexus to modulate relaxation of the distal esophageal wall and LES[57-59]. Reported studies have suggested a role for this neuropeptide as chief element in the maintenance of neuro-endocrine immune system communication that activates signal transduction through specific receptors present on immune cells[60]. Receptor of vasoactive intestinal polypeptide (VIPR1) belongs to the secretin receptor family, a group of G-protein coupled receptors expressed by different immune cells, including T cells, macrophages and dendritic cells[56]. VIPR1 is present on myenteric neurons of the distal esophagus and LES; continued inflammation leads to the impairment of VIPR1 signaling, which alters the effect of VIP on myenteric neurons that progresses to ganglion cell loss and nerve fiber fibrosis[8,29,32-34,36,53]. A few further studies among patients with rheumatic diseases showed the receptor down-regulation of the VIPR1 gene resulting in decreased signaling[61-64]. Paladini et al[64,65] reported five single nucleotide polymorphisms in the VIPR1 gene in patients with achalasia cardia which included (rs421558) Intron-1, (rs437876) Intron-4, (rs417387) Intron-6, rs896 and rs9677 (3’UTR) and they found that the presence of A allele at (rs421558) Intron-1 and C allele at rs896 (3’UTR) was associated with a less efficient down-regulation of the receptor. Hence, AC haplotype may protect from the disease by down-regulation of VIPR1 receptor during inflammation.

Interleukin-23 receptor polymorphism: The interleukin-23 receptor (IL-23R) gene, located on chromosome Ip31, encodes for heterodimeric subunits of the IL-23R complex[66]. IL-23R is a type I trans-membrane protein expressed on Th1 derived T-cells which produce IL-17, designated as Th17 cells. Previous data support a role for Th17 cells and these cytokines in inflammatory and autoimmune processes[67]. Activated JAK-STAT signaling pathway by IL-23 binds with the IL-23R/IL-12β1 receptor, which influences the number of downstream immune responses[66]. Reported studies showed that IL-23R is associated with inflammatory as well as chronic autoimmune disorders[68-74]. In a single nucleotide polymorphism of the IL-23R gene, arginine replaces glutamine at codon 381. One study reported IL-23R coding variant 381Gln was a protective allele, whereas another study found this variant to be a risk factor. de León et al[75] reported coding variant 381Gln of IL-23R was significantly more common in patients with achalasia as compared with healthy controls. Hence, this 381Gln variant of IL-23R polymorphism could be a risk factor for achalasia cardia.

Protein tyrosine phosphatase non-receptor 22 gene polymorphism: The protein tyrosine phosphatase non-receptor 22 (PTPN22) gene is located on chromosome 1p13.3-p13, a region associated with autoimmune disease[75,76]. It encodes a lymphoid specific phosphatase known as Lyp. Lyp is an intracellular protein tyrosine phosphatase and an important down-regulator of T-cell activation[77]. The PTPN22 gene exhibits a single nucleotide polymorphism at position 1858C/T, which leads to a replacement in codon 620 of Arg (R) to Trp (W). A study showed that Lyp-W620 had more phosphatase activity, which could slow down T-cell signaling more effectively than Lyp-R620. In a different population it has already been reported that the PTPN22 T allele is a risk factor for autoimmune diseases[78-83]. Santiago et al[84] reported that PTPN22 C1858T polymorphism increased risk of achalasia in a Spanish population.

CONCLUSION

Achalasia is caused by loss of inhibitory ganglion in the myenteric plexus in the esophagus. Gradual progression of neuronal degeneration is associated with progression of the disease from vigorous to classic achalasia. Though several studies have attempted to explore initiating agents that may cause the disease, the exact factors responsible for the degeneration of ganglion cells in the myenteric plexus are poorly understood. The disease is likely to be multi-factorial involving host genetic factors, autoimmunity, and environmental factors such as infections. More studies are needed to explore the exact cause of this enigmatic disease.

Footnotes

Peer reviewers: Ho-Young Song, MD, PhD, Professor of Diagnostic Radiology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap 2-dong, Songpa-gu, Seoul 138-736, South Korea; Dr. Dinesh Vyas, Department of Minimally and Endosopic Surgery, St John Mercy Hospital, 851 E Fifth Street, Washington, MO 63090, United States

S- Editor Cheng JX L- Editor Logan S E- Editor Zheng XM

References
1.  Ghoshal UC, Kumar S, Saraswat VA, Aggarwal R, Misra A, Choudhuri G. Long-term follow-up after pneumatic dilation for achalasia cardia: factors associated with treatment failure and recurrence. Am J Gastroenterol. 2004;99:2304-2310.  [PubMed]  [DOI]
2.  Francis DL, Katzka DA. Achalasia: update on the disease and its treatment. Gastroenterology. 2010;139:369-374.  [PubMed]  [DOI]
3.  Willis T.  harmaceutice rationalis sive diatribe de medicamentorum operationibus in humano corpore. 1674;.  [PubMed]  [DOI]
4.  Hurst AF. The treatment of achalasia of the cardia: so-called ‘cardiospasm’. Lancet. 1927;209:618-619.  [PubMed]  [DOI]
5.  Rake AT. Achalasia and Degeneration of Auerbach's Plexus. Proc R Soc Med. 1928;21:1775-1777.  [PubMed]  [DOI]
6.  Crist J, Gidda JS, Goyal RK. Intramural mechanism of esophageal peristalsis: roles of cholinergic and noncholinergic nerves. Proc Natl Acad Sci USA. 1984;81:3595-3599.  [PubMed]  [DOI]
7.  Goyal RK, Chaudhury A. Physiology of normal esophageal motility. J Clin Gastroenterol. 2008;42:610-619.  [PubMed]  [DOI]
8.  Park W, Vaezi MF. Etiology and pathogenesis of achalasia: the current understanding. Am J Gastroenterol. 2005;100:1404-1414.  [PubMed]  [DOI]
9.  Meshkinpour H, Haghighat P, Dutton C. Clinical spectrum of esophageal aperistalsis in the elderly. Am J Gastroenterol. 1994;89:1480-1483.  [PubMed]  [DOI]
10.  Misiewicz JJ, Waller SL, Anthony PP, Gummer JW. Achalasia of the cardia: pharmacology and histopathology of isolated cardiac sphincteric muscle from patients with and without achalasia. Q J Med. 1969;38:17-30.  [PubMed]  [DOI]
11.  Paterson WG. Esophageal and lower esophageal sphincter response to balloon distention in patients with achalasia. Dig Dis Sci. 1997;42:106-112.  [PubMed]  [DOI]
12.  Holloway RH, Wyman JB, Dent J. Failure of transient lower oesophageal sphincter relaxation in response to gastric distension in patients with achalasia: evidence for neural mediation of transient lower oesophageal sphincter relaxations. Gut. 1989;30:762-767.  [PubMed]  [DOI]
13.  Cassella RR, Brown AL, Sayre GP, Ellis FH. Achalasia of the esophagus: pathologic and etiologic considerations. Ann Surg. 1964;160:474-487.  [PubMed]  [DOI]
14.  Kravitz JJ, Snape WJ, Cohen S. Effect of thoracic vagotomy and vagal stimulation on esophageal function. Am J Physiol. 1978;234:E359-E364.  [PubMed]  [DOI]
15.  Khajanchee YS, VanAndel R, Jobe BA, Barra MJ, Hansen PD, Swanstrom LL. Electrical stimulation of the vagus nerve restores motility in an animal model of achalasia. J Gastrointest Surg. 2003;7:843-849; discussion 849.  [PubMed]  [DOI]
16.  Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology. 1984;87:848-856.  [PubMed]  [DOI]
17.  Eckardt VF, Krause J, Bolle D. Gastrointestinal transit and gastric acid secretion in patients with achalasia. Dig Dis Sci. 1989;34:665-671.  [PubMed]  [DOI]
18.  Atkinson M, Ogilvie AL, Robertson CS, Smart HL. Vagal function in achalasia of the cardia. Q J Med. 1987;63:297-303.  [PubMed]  [DOI]
19.  Chakder S, Rosenthal GJ, Rattan S. In vivo and in vitro influence of human recombinant hemoglobin on esophageal function. Am J Physiol. 1995;268:G443-G450.  [PubMed]  [DOI]
20.  Murray JA, Ledlow A, Launspach J, Evans D, Loveday M, Conklin JL. The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology. 1995;109:1241-1248.  [PubMed]  [DOI]
21.  Sivarao DV, Mashimo HL, Thatte HS, Goyal RK. Lower esophageal sphincter is achalasic in nNOS(-/-) and hypotensive in W/W(v) mutant mice. Gastroenterology. 2001;121:34-42.  [PubMed]  [DOI]
22.  Jones DB, Mayberry JF, Rhodes J, Munro J. Preliminary report of an association between measles virus and achalasia. J Clin Pathol. 1983;36:655-657.  [PubMed]  [DOI]
23.  Robertson CS, Martin BA, Atkinson M. Varicella-zoster virus DNA in the oesophageal myenteric plexus in achalasia. Gut. 1993;34:299-302.  [PubMed]  [DOI]
24.  Paliwal M, Prasanna KS, Saraswat VA, Misra A, Krishnani N, Ghoshal UC. Varicella zoster cranial polyneuropathy presenting with Dysphagia, esophagitis and gastroparesis. J Neurogastroenterol Motil. 2011;17:192-194.  [PubMed]  [DOI]
25.  Niwamoto H, Okamoto E, Fujimoto J, Takeuchi M, Furuyama J, Yamamoto Y. Are human herpes viruses or measles virus associated with esophageal achalasia? Dig Dis Sci. 1995;40:859-864.  [PubMed]  [DOI]
26.  Birgisson S, Galinski MS, Goldblum JR, Rice TW, Richter JE. Achalasia is not associated with measles or known herpes and human papilloma viruses. Dig Dis Sci. 1997;42:300-306.  [PubMed]  [DOI]
27.  Facco M, Brun P, Baesso I, Costantini M, Rizzetto C, Berto A, Baldan N, Palù G, Semenzato G, Castagliuolo I. T cells in the myenteric plexus of achalasia patients show a skewed TCR repertoire and react to HSV-1 antigens. Am J Gastroenterol. 2008;103:1598-1609.  [PubMed]  [DOI]
28.  de Oliveira RB, Rezende Filho J, Dantas RO, Iazigi N. The spectrum of esophageal motor disorders in Chagas' disease. Am J Gastroenterol. 1995;90:1119-1124.  [PubMed]  [DOI]
29.  Goldblum JR, Rice TW, Richter JE. Histopathologic features in esophagomyotomy specimens from patients with achalasia. Gastroenterology. 1996;111:648-654.  [PubMed]  [DOI]
30.  Raymond L, Lach B, Shamji FM. Inflammatory aetiology of primary oesophageal achalasia: an immunohistochemical and ultrastructural study of Auerbach's plexus. Histopathology. 1999;35:445-453.  [PubMed]  [DOI]
31.  Akiho H, Ihara E, Motomura Y, Nakamura K. Cytokine-induced alterations of gastrointestinal motility in gastrointestinal disorders. World J Gastrointest Pathophysiol. 2011;2:72-81.  [PubMed]  [DOI]
32.  Storch WB, Eckardt VF, Wienbeck M, Eberl T, Auer PG, Hecker A, Junginger T, Bosseckert H. Autoantibodies to Auerbach's plexus in achalasia. Cell Mol Biol (Noisy-le-grand). 1995;41:1033-1038.  [PubMed]  [DOI]
33.  Verne GN, Sallustio JE, Eaker EY. Anti-myenteric neuronal antibodies in patients with achalasia. A prospective study. Dig Dis Sci. 1997;42:307-313.  [PubMed]  [DOI]
34.  Ruiz-de-León A, Mendoza J, Sevilla-Mantilla C, Fernández AM, Pérez-de-la-Serna J, Gónzalez VA, Rey E, Figueredo A, Díaz-Rubio M, De-la-Concha EG. Myenteric antiplexus antibodies and class II HLA in achalasia. Dig Dis Sci. 2002;47:15-19.  [PubMed]  [DOI]
35.  Goin JC, Sterin-Borda L, Bilder CR, Varrica LM, Iantorno G, Ríos MC, Borda E. Functional implications of circulating muscarinic cholinergic receptor autoantibodies in chagasic patients with achalasia. Gastroenterology. 1999;117:798-805.  [PubMed]  [DOI]
36.  Moses PL, Ellis LM, Anees MR, Ho W, Rothstein RI, Meddings JB, Sharkey KA, Mawe GM. Antineuronal antibodies in idiopathic achalasia and gastro-oesophageal reflux disease. Gut. 2003;52:629-636.  [PubMed]  [DOI]
37.  Wong RK, Maydonovitch CL, Metz SJ, Baker JR. Significant DQw1 association in achalasia. Dig Dis Sci. 1989;34:349-352.  [PubMed]  [DOI]
38.  De la Concha EG, Fernandez-Arquero M, Mendoza JL, Conejero L, Figueredo MA, Perez de la Serna J, Diaz-Rubio M, Ruiz de Leon A. Contribution of HLA class II genes to susceptibility in achalasia. Tissue Antigens. 1998;52:381-384.  [PubMed]  [DOI]
39.  Verne GN, Hahn AB, Pineau BC, Hoffman BJ, Wojciechowski BW, Wu WC. Association of HLA-DR and -DQ alleles with idiopathic achalasia. Gastroenterology. 1999;117:26-31.  [PubMed]  [DOI]
40.  Latiano A, De Giorgio R, Volta U, Palmieri O, Zagaria C, Stanghellini V, Barbara G, Mangia A, Andriulli A, Corinaldesi R. HLA and enteric antineuronal antibodies in patients with achalasia. Neurogastroenterol Motil. 2006;18:520-525.  [PubMed]  [DOI]
41.  Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today. 1993;14:426-430.  [PubMed]  [DOI]
42.  Stein DT, Knauer CM. Achalasia in monozygotic twins. Dig Dis Sci. 1982;27:636-640.  [PubMed]  [DOI]
43.  Chulia Orti F, Tuset Ruiz JA, Tome Toyosato A, Medina Chulia E, González Muñoz C. [Achalasia of the cardia in 2 brothers, not twins]. Rev Esp Enferm Apar Dig. 1982;61:248-253.  [PubMed]  [DOI]
44.  Stoddard CJ, Johnson AG. Achalasia in siblings. Br J Surg. 1982;69:84-85.  [PubMed]  [DOI]
45.  Tryhus MR, Davis M, Griffith JK, Ablin DS, Gogel HK. Familial achalasia in two siblings: significance of possible hereditary role. J Pediatr Surg. 1989;24:292-295.  [PubMed]  [DOI]
46.  Frieling T, Berges W, Borchard F, Lübke HJ, Enck P, Wienbeck M. Family occurrence of achalasia and diffuse spasm of the oesophagus. Gut. 1988;29:1595-1602.  [PubMed]  [DOI]
47.  Jung KW, Yoon IJ, Kim do H, Chung JW, Choi KS, Choi KD, Song HJ, Lee GH, Myung SJ, Kim JH. Genetic evaluation of ALADIN gene in early-onset achalasia and alacrima patients. J Neurogastroenterol Motil. 2011;17:169-173.  [PubMed]  [DOI]
48.  Di Nardo G, Tullio-Pelet A, Annese V, Stanghellini V, Barbara G, Latiano A, Andriulli A, Cremon C, Salvioli B, Volta U. Idiopathic achalasia is not allelic to alacrima achalasia adrenal insufficiency syndrome at the ALADIN locus. Dig Liver Dis. 2005;37:312-315.  [PubMed]  [DOI]
49.  Johnston BT, Colcher A, Li Q, Gideon RM, Castell JA, Castell DO. Repetitive proximal esophageal contractions: a new manometric finding and a possible further link between Parkinson's disease and achalasia. Dysphagia. 2001;16:186-189.  [PubMed]  [DOI]
50.  Zárate N, Mearin F, Gil-Vernet JM, Camarasa F, Malagelada JR. Achalasia and Down's syndrome: coincidental association or something else? Am J Gastroenterol. 1999;94:1674-1677.  [PubMed]  [DOI]
51.  Gockel HR, Gockel I, Schimanski CC, Schier F, Schumacher J, Nöthen MM, Lang H, Müller M, Eckardt AJ, Eckardt VF. Etiopathological aspects of achalasia: lessons learned with Hirschsprung's disease. Dis Esophagus. 2011;Epub ahead of print.  [PubMed]  [DOI]
52.  Mearin F, Mourelle M, Guarner F, Salas A, Riveros-Moreno V, Moncada S, Malagelada JR. Patients with achalasia lack nitric oxide synthase in the gastro-oesophageal junction. Eur J Clin Invest. 1993;23:724-728.  [PubMed]  [DOI]
53.  De Giorgio R, Di Simone MP, Stanghellini V, Barbara G, Tonini M, Salvioli B, Mattioli S, Corinaldesi R. Esophageal and gastric nitric oxide synthesizing innervation in primary achalasia. Am J Gastroenterol. 1999;94:2357-2362.  [PubMed]  [DOI]
54.  Vigo AG, Martínez A, de la Concha EG, Urcelay E, Ruiz de León A. Suggested association of NOS2A polymorphism in idiopathic achalasia: no evidence in a large case-control study. Am J Gastroenterol. 2009;104:1326-1327.  [PubMed]  [DOI]
55.  Mearin F, García-González MA, Strunk M, Zárate N, Malagelada JR, Lanas A. Association between achalasia and nitric oxide synthase gene polymorphisms. Am J Gastroenterol. 2006;101:1979-1984.  [PubMed]  [DOI]
56.  Sreedharan SP, Huang JX, Cheung MC, Goetzl EJ. Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci USA. 1995;92:2939-2943.  [PubMed]  [DOI]
57.  Pozo D, Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J. 2004;18:1325-1334.  [PubMed]  [DOI]
58.  Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood. 2006;107:3632-3638.  [PubMed]  [DOI]
59.  Parkman HP, Pagano AP, Ryan JP. PACAP and VIP inhibit pyloric muscle through VIP/PACAP-preferring receptors. Regul Pept. 1997;71:185-190.  [PubMed]  [DOI]
60.  Voice JK, Dorsam G, Chan RC, Grinninger C, Kong Y, Goetzl EJ. Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul Pept. 2002;109:199-208.  [PubMed]  [DOI]
61.  Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum. 2006;54:864-876.  [PubMed]  [DOI]
62.  Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P, Caro M, Orozco G, Gonzalez-Rey E, Martin J. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Arthritis Rheum. 2008;58:1010-1019.  [PubMed]  [DOI]
63.  Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum. 2008;58:1086-1095.  [PubMed]  [DOI]
64.  Paladini F, Cocco E, Cauli A, Cascino I, Vacca A, Belfiore F, Fiorillo MT, Mathieu A, Sorrentino R. A functional polymorphism of the vasoactive intestinal peptide receptor 1 gene correlates with the presence of HLA-B*2705 in Sardinia. Genes Immun. 2008;9:659-667.  [PubMed]  [DOI]
65.  Paladini F, Cocco E, Cascino I, Belfiore F, Badiali D, Piretta L, Alghisi F, Anzini F, Fiorillo MT, Corazziari E. Age-dependent association of idiopathic achalasia with vasoactive intestinal peptide receptor 1 gene. Neurogastroenterol Motil. 2009;21:597-602.  [PubMed]  [DOI]
66.  Lankford CS, Frucht DM. A unique role for IL-23 in promoting cellular immunity. J Leukoc Biol. 2003;73:49-56.  [PubMed]  [DOI]
67.  Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235-238.  [PubMed]  [DOI]
68.  McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006;27:17-23.  [PubMed]  [DOI]
69.  Hollis-Moffatt JE, Merriman ME, Rodger RA, Rowley KA, Chapman PT, Dalbeth N, Gow PJ, Harrison AA, Highton J, Jones PB. Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis. Ann Rheum Dis. 2009;68:1340-1344.  [PubMed]  [DOI]
70.  Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461-1463.  [PubMed]  [DOI]
71.  Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273-290.  [PubMed]  [DOI]
72.  Einarsdottir E, Koskinen LL, Dukes E, Kainu K, Suomela S, Lappalainen M, Ziberna F, Korponay-Szabo IR, Kurppa K, Kaukinen K. IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease. BMC Med Genet. 2009;10:8.  [PubMed]  [DOI]
73.  Filer C, Ho P, Smith RL, Griffiths C, Young HS, Worthington J, Bruce IN, Barton A. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum. 2008;58:3705-3709.  [PubMed]  [DOI]
74.  Núñez C, Dema B, Cénit MC, Polanco I, Maluenda C, Arroyo R, de las Heras V, Bartolomé M, de la Concha EG, Urcelay E. IL23R: a susceptibility locus for celiac disease and multiple sclerosis? Genes Immun. 2008;9:289-293.  [PubMed]  [DOI]
75.  de León AR, de la Serna JP, Santiago JL, Sevilla C, Fernández-Arquero M, de la Concha EG, Nuñez C, Urcelay E, Vigo AG. Association between idiopathic achalasia and IL23R gene. Neurogastroenterol Motil. 2010;22:734-738, e218.  [PubMed]  [DOI]
76.  Gaffney PM, Kearns GM, Shark KB, Ortmann WA, Selby SA, Malmgren ML, Rohlf KE, Ockenden TC, Messner RP, King RA. A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families. Proc Natl Acad Sci USA. 1998;95:14875-14879.  [PubMed]  [DOI]
77.  Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Etzel C, Damle A, Xiao X, Chen D, Lum RF. Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum. 2003;48:906-916.  [PubMed]  [DOI]
78.  Vang T, Congia M, Macis MD, Musumeci L, Orrú V, Zavattari P, Nika K, Tautz L, Taskén K, Cucca F. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet. 2005;37:1317-1319.  [PubMed]  [DOI]
79.  Gregersen PK, Lee HS, Batliwalla F, Begovich AB. PTPN22: setting thresholds for autoimmunity. Semin Immunol. 2006;18:214-223.  [PubMed]  [DOI]
80.  Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004;75:330-337.  [PubMed]  [DOI]
81.  Carlton VE, Hu X, Chokkalingam AP, Schrodi SJ, Brandon R, Alexander HC, Chang M, Catanese JJ, Leong DU, Ardlie KG. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am J Hum Genet. 2005;77:567-581.  [PubMed]  [DOI]
82.  Orozco G, Sánchez E, González-Gay MA, López-Nevot MA, Torres B, Cáliz R, Ortego-Centeno N, Jiménez-Alonso J, Pascual-Salcedo D, Balsa A. Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum. 2005;52:219-224.  [PubMed]  [DOI]
83.  van Oene M, Wintle RF, Liu X, Yazdanpanah M, Gu X, Newman B, Kwan A, Johnson B, Owen J, Greer W. Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations. Arthritis Rheum. 2005;52:1993-1998.  [PubMed]  [DOI]
84.  Santiago JL, Martínez A, Benito MS, Ruiz de León A, Mendoza JL, Fernández-Arquero M, Figueredo MA, de la Concha EG, Urcelay E. Gender-specific association of the PTPN22 C1858T polymorphism with achalasia. Hum Immunol. 2007;68:867-870.  [PubMed]  [DOI]